Celon Pharma (FRA:8RP) Cyclically Adjusted FCF per Share: €-0.18 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8RP Celon Pharma SA FRA:8RP
44 GF Score
Price €4.65
GF Value €5.81
! 3 Warning Signs
View Full Analysis

What is Celon Pharma Cyclically Adjusted FCF per Share?

Celon Pharma FRA:8RP +0.76% 44 Cyclically Adjusted FCF per Share is €-0.18 as of Mar. 2026. GuruFocus rates FRA:8RP with a GF Score™ of 44/100 and a GF Value™ of €5.81. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Celon Pharma's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.083. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.18 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-21), Celon Pharma's current stock price is €4.65. Celon Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-0.18. Celon Pharma's Cyclically Adjusted Price-to-FCF of today is .


Celon Pharma  (FRA:8RP) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Celon Pharma Cyclically Adjusted FCF per Share Related Terms


Celon Pharma Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Celon Pharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma Cyclically Adjusted FCF per Share Chart

Celon Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.15

Celon Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.17 -0.15 -0.18

FRA:8RP vs ZTS, UTHR, VTRS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celon Pharma Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Celon Pharma's Cyclically Adjusted Price-to-FCF falls into.


FRA:8RP
44GF Score
Celon Pharma SA FRA:8RP
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celon Pharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Celon Pharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.083/163.0700*163.0700
=-0.083

Current CPI (Mar. 2026) = 163.0700.

Celon Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.009 99.552 0.015
201609 0.013 99.064 0.021
201612 -0.020 100.366 -0.032
201703 0.026 101.018 0.042
201706 -0.050 101.180 -0.081
201709 0.018 101.343 0.029
201712 -0.025 102.564 -0.040
201803 -0.025 102.564 -0.040
201806 -0.011 103.378 -0.017
201809 -0.094 103.378 -0.148
201812 0.015 103.785 0.024
201903 0.019 104.274 0.030
201906 -0.162 105.983 -0.249
201909 -0.154 105.983 -0.237
201912 -0.061 107.123 -0.093
202003 -0.059 109.076 -0.088
202006 -0.185 109.402 -0.276
202009 0.016 109.320 0.024
202012 0.087 109.565 0.129
202103 -0.011 112.658 -0.016
202106 -0.071 113.960 -0.102
202109 0.037 115.588 0.052
202112 0.056 119.088 0.077
202203 -0.097 125.031 -0.127
202206 -0.037 131.705 -0.046
202209 -0.091 135.531 -0.109
202212 0.051 139.113 0.060
202303 -0.113 145.950 -0.126
202306 -0.088 147.009 -0.098
202309 0.009 146.113 0.010
202312 0.004 147.741 0.004
202403 -0.028 149.044 -0.031
202406 -0.037 150.997 -0.040
202409 -0.081 153.439 -0.086
202412 -0.002 154.660 -0.002
202503 -0.065 157.021 -0.068
202506 -0.080 157.509 -0.083
202509 -0.031 158.000 -0.032
202512 0.154 158.320 0.159
202603 -0.083 163.070 -0.083

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.18 mean?
Celon Pharma (FRA:8RP) has a Cyclically Adjusted FCF per Share of €-0.18 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Celon Pharma and its competitors.
Is Celon Pharma's Cyclically Adjusted FCF per Share too high?
Celon Pharma's current Cyclically Adjusted FCF per Share is €-0.18. Overall, Celon Pharma has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Cyclically Adjusted FCF per Share compare to ZTS and UTHR?
Celon Pharma's Cyclically Adjusted FCF per Share of €-0.18 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Celon Pharma and its competitors. Celon Pharma's current Cyclically Adjusted FCF per Share is €-0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Celon Pharma (FRA:8RP) has a current Cyclically Adjusted FCF per Share of €-0.18. The stock's GF Value™ is €5.81, compared to a current price of €4.65 — trading 20% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.18. Celon Pharma's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Celon Pharma (FRA:8RP), the current Cyclically Adjusted FCF per Share is €-0.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celon Pharma (FRA:8RP) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of €4.65 is trading 20% below its estimated GF Value™ of €5.81.

Key valuation signals for FRA:8RP:

  • Cyclically Adjusted FCF per Share: €-0.18
  • GF Value™: €5.81 vs. price of €4.65 (20% below fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the FRA:8RP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Celon Pharma Business Description

Other Exchanges CLN:Poland
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
44GF Score

Get the complete analysis for FRA:8RP

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.65
Price
€5.81
GF Value